Get the Stockscreener App
0.236
2.88%
0.0066
Carisma Therapeutics Inc stock is traded at $0.236, with a volume of 812.15K.
It is up +2.88% in the last 24 hours and down -38.80% over the past month.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
See More
Previous Close:
$0.2294
Open:
$0.2282
24h Volume:
812.15K
Relative Volume:
0.06
Market Cap:
$9.86M
Revenue:
$20.27M
Net Income/Loss:
$-63.80M
P/E Ratio:
-0.1553
EPS:
-1.52
Net Cash Flow:
$-68.35M
1W Performance:
-19.18%
1M Performance:
-38.80%
6M Performance:
-47.58%
1Y Performance:
-80.17%
1-Day Range:
$0.2146
$0.2432
1-Week Range:
$0.2102
$0.3067
52-Week Range:
$0.1417
$1.27
Carisma Therapeutics Inc Stock (CARM) Company Profile
Name
Carisma Therapeutics Inc
Sector
Industry
Phone
(267) 491-6422
Address
3675 MARKET STREET, PHILADELPHIA
Compare CARM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.236 | 11.66M | 20.27M | -63.80M | -68.35M | -1.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-10-24 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-11-24 | Initiated | BTIG Research | Buy |
| Oct-03-23 | Initiated | CapitalOne | Overweight |
| Jul-06-23 | Initiated | Evercore ISI | Outperform |
| May-31-23 | Upgrade | Jefferies | Hold → Buy |
| May-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
View All
Carisma Therapeutics Inc Stock (CARM) Latest News
Has Carisma Therapeutics Inc. formed a bullish divergenceWatch List & Reliable Price Breakout Alerts - Newser
Carisma Therapeutics Inc. recovery potential after sell offRisk Management & Technical Pattern Alert System - Newser
Building trade automation scripts for Carisma Therapeutics Inc.July 2025 Reactions & Daily Profit Focused Stock Screening - Newser
Visual analytics tools that track Carisma Therapeutics Inc. performanceEarnings Recap Summary & Weekly High Return Stock Opportunities - Newser
Full technical analysis of Carisma Therapeutics Inc. stock2025 Valuation Update & High Accuracy Trade Alerts - Newser
Carisma Therapeutics Inc. stock prediction for this weekMarket Sentiment Report & Short-Term High Return Strategies - Newser
Applying chart zones and confluence areas to Carisma Therapeutics Inc.Weekly Gains Report & Reliable Intraday Trade Plans - Newser
Carisma Therapeutics Inc. (NASDAQ:CARM) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
What earnings revisions data tells us about Carisma Therapeutics Inc.2025 Technical Overview & Verified Trade Idea Suggestions - Newser
Applying big data sentiment scoring on Carisma Therapeutics Inc.July 2025 Sector Moves & Weekly Market Pulse Updates - Newser
What makes Carisma Therapeutics Inc. stock price move sharplyWeekly Stock Recap & Growth Focused Stock Reports - newsyoung.net
How to forecast Carisma Therapeutics Inc. trends using time seriesTrade Volume Report & AI Powered Buy/Sell Recommendations - Newser
Top Risks to Consider Before Buying Carisma Therapeutics Inc. StockEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
Chart based analysis of Carisma Therapeutics Inc. trendsRate Hike & High Return Stock Watch Alerts - Newser
How Carisma Therapeutics Inc. stock performs during market volatilityMarket Weekly Review & Safe Capital Growth Tips - Newser
Can Carisma Therapeutics Inc. Overcome Bearish SentimentTrade Volume Summary & Free Long-Term Investment Growth Plans - sundaytimes.kr
Carisma Therapeutics Inc. stock outlook for YEAR2025 Growth vs Value & Consistent Income Trade Recommendations - Newser
Published on: 2025-08-17 17:18:40 - beatles.ru
Pattern recognition hints at Carisma Therapeutics Inc. upside2025 Institutional Moves & Community Consensus Picks - Newser
Using Ichimoku Cloud for Carisma Therapeutics Inc. technicalsWeekly Investment Summary & Daily Volume Surge Trade Alerts - Newser
Will earnings trigger a reversal in Carisma Therapeutics Inc.Portfolio Value Report & Stock Portfolio Risk Control - Newser
Is Carisma Therapeutics Inc. stock bottoming out2025 Market Sentiment & Consistent Income Trade Ideas - Newser
Carisma Therapeutics (NASDAQ:CARM) versus Crinetics Pharmaceuticals (NASDAQ:CRNX) Critical Analysis - Defense World
Will Carisma Therapeutics Inc. Sustain Its Chart Breakout2025 Big Picture & Real-Time Chart Pattern Alerts - beatles.ru
Investors Hope for Bounce in Carisma Therapeutics Inc. After Selloff2025 Sector Review & Daily Stock Momentum Reports - sundaytimes.kr
Is This the Dip to Buy in Carisma Therapeutics Inc.Market Risk Report & Consistent Return Strategy Ideas - sundaytimes.kr
Trendlines Suggest Carisma Therapeutics Inc. May Bottom Out SoonProduct Launch & High Conviction Buy Zone Picks - beatles.ru
Is this a good reentry point in Carisma Therapeutics Inc.Forecast Cut & AI Based Buy and Sell Signals - Newser
Buy Signal for Carisma Therapeutics Inc. Stock Key Technical Indicators to WatchFree Risk-Adjusted Picks With Exit Strategy - Newser
Carisma Therapeutics Approves Reverse Stock Split - The Globe and Mail
Carisma Therapeutics (CARM) Projected to Post Quarterly Earnings on Thursday - Defense World
CARISMA Therapeutics 2025 Q1 Earnings Loss Narrows by 51.2% - AInvest
CARISMA Therapeutics: D. Boral Capital maintains Buy, PT raised to $1 from $0.90 - AInvest
Carisma Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Carisma Therapeutics Inc. (NASDAQ:CARM) - Defense World
Carisma Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Is it the right time to buy Carisma Therapeutics Inc. stockFree Market Volatility Navigation Tips - Jammu Links News
Is Carisma Therapeutics Inc. a good long term investmentCapitalize on market momentum for maximum gains - Jammu Links News
How many analysts rate Carisma Therapeutics Inc. as a “Buy”Capitalize on emerging investment opportunities - Jammu Links News
Why is Carisma Therapeutics Inc. stock attracting strong analyst attentionExplosive capital appreciation - Jammu Links News
Carisma Therapeutics Inc Stock (CARM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):